BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly to $865 from $710 and keeps an Outperform rating on the shares after its Q4 earnings beat and guidance. Consensus estimates again underestimated tirzepatide growth as demand continues to outstrip supply, and this ongoing demand further supports BMO’s raised target price as the firm sees no signs of this stopping soon, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Gains after Strong Q4 Results
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
- Eli Lilly sees FY24 EPS $12.20-$12.70, consensus $12.43
- Eli Lilly reports Q4 EPS $2.49, consensus $2.19